Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

A mosaic nanoparticle vaccine for HCV; plus mitochondrial zinc finger base editors and more

BioCentury’s roundup of translational news

By Danielle Golovin, Staff Writer
December 8, 2022 12:26 AM UTC

A team led by University of Amsterdam researchers, including Icosavax Inc. (NASDAQ:ICVX) co-founder Neil King, revealed in Nature Communications a mosaic nanoparticle vaccine co-displaying six different recombinant E2E1 glycoprotein immunogens that increased HCV neutralization compared with monovalent E2E1 nanoparticles in a rabbit model.

Icosavax has licensed patent applications regarding the nanoparticle system...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Broad Institute of Mit and Harvard

Chalmers University of Technology

Cirqle Biomedical Contraception ApS

Elypta AB

Icosavax Inc.

KTH Royal Institute of Technology

LogicBio Therapeutics Inc.